Wells Fargo & Company Forecasts Strong Price Appreciation for McKesson (NYSE:MCK) Stock

McKesson (NYSE:MCK) had its price target raised by equities research analysts at Wells Fargo & Company from $914.00 to $925.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential downside of 2.88% from the stock’s current price.

A number of other research analysts also recently issued reports on MCK. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group upped their price target on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Robert W. Baird set a $968.00 target price on McKesson in a research report on Wednesday, January 14th. Zacks Research lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Barclays initiated coverage on McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus price target of $918.93.

McKesson Stock Performance

McKesson stock traded up $130.43 during trading on Thursday, hitting $952.43. The company’s stock had a trading volume of 1,194,716 shares, compared to its average volume of 666,672. The stock has a market capitalization of $117.56 billion, a price-to-earnings ratio of 29.63, a P/E/G ratio of 1.40 and a beta of 0.40. McKesson has a 1-year low of $570.51 and a 1-year high of $964.94. The stock’s fifty day moving average is $825.54 and its 200 day moving average is $776.66.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts anticipate that McKesson will post 32.77 EPS for the current fiscal year.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $861.63, for a total value of $283,476.27. Following the transaction, the chief accounting officer directly owned 328 shares of the company’s stock, valued at $282,614.64. The trade was a 50.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.08% of the company’s stock.

Institutional Investors Weigh In On McKesson

Several institutional investors have recently modified their holdings of the business. DNB Asset Management AS boosted its position in McKesson by 1.6% in the 4th quarter. DNB Asset Management AS now owns 44,671 shares of the company’s stock valued at $36,643,000 after buying an additional 714 shares during the period. Convergence Investment Partners LLC lifted its position in McKesson by 16.3% during the fourth quarter. Convergence Investment Partners LLC now owns 2,853 shares of the company’s stock valued at $2,340,000 after purchasing an additional 400 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of McKesson by 403.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 43,459 shares of the company’s stock valued at $35,649,000 after purchasing an additional 34,820 shares in the last quarter. Left Brain Wealth Management LLC lifted its position in shares of McKesson by 39.0% during the 4th quarter. Left Brain Wealth Management LLC now owns 6,848 shares of the company’s stock valued at $5,617,000 after buying an additional 1,923 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of McKesson by 2.1% during the fourth quarter. Thrivent Financial for Lutherans now owns 16,222 shares of the company’s stock worth $13,365,000 after purchasing an additional 341 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results: McKesson reported EPS above consensus ($9.34) and revenue up ~11.4% year‑over‑year — a core trigger for the rally. McKesson Q3 results (MarketBeat)
• Positive Sentiment: Company raised full‑year adjusted EPS guidance to $38.80–$39.20 (above consensus), signaling confidence in profit momentum. Business Wire: McKesson raises full‑year guidance
• Positive Sentiment: Management and reporters point to strong specialty and oncology drug distribution as the growth driver behind the upgraded profit outlook. Reuters: McKesson boosts 2026 forecast
• Neutral Sentiment: Mizuho nudged its price target slightly higher to $885 but kept a “neutral” rating — a modest house view that doesn’t endorse a buy/sell shift. Benzinga: Mizuho price target update
• Neutral Sentiment: Investor resources (earnings transcript, slide deck, conference call) were posted — useful for diligence but not new fundamental news. Seeking Alpha: Earnings transcript
• Neutral Sentiment: McKesson completed its exit from the European market — a strategic move whose net impact on margins and growth is mixed and depends on redeployment of capital. HMENews: McKesson exits Europe
• Negative Sentiment: Operating cash flow weakened materially in the quarter (reported declines in cash from operations), a potential red flag for free cash flow conversion despite higher reported earnings. QuiverQuant: Weak operating cash flow
• Negative Sentiment: Recent insider selling (multiple disclosed sales) may concern some investors about near‑term insider conviction. QuiverQuant: Insider transactions
• Negative Sentiment: Median analyst price target data cited in coverage sits below the current market price (some variability across firms), implying some analysts view upside as limited at current levels. QuiverQuant: Analyst targets & ratings

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.